Floatz logo

cd19/cd22-bispecific car-t cells

B-cell Acute Lymphoblastic Leukemia

Beijing Tongren HospitalCell therapyPhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

140 Active assets in the B-cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

cd19/cd22-bispecific car-t cells is also rated in:

B-Cell Lymphoblastic Leukemia/LymphomaDormant
B
Indicative ·
60 / 100
View asset →
B-Cell Lymphoma Stage IDormant
B
Indicative ·
60 / 100
View asset →
Large B-Cell Lymphoma (LBCL)Dormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →